T47D/S5 Cell Line
Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society
- Datasheet
- References (8)
- Inventor Info
Info
| Catalogue Number | 152111 |
| Antigen/Gene or Protein Targets | Oestrogen receptor |
| Parental Line | T47D |
| Host | Human |
| Tissue | Breast |
| Disease Keywords | Breast cancer |
| Model | Tumour line |
| Relevance | The T47D/S5 Cell line is the control for the fulvestrant resistant T47D/182R-1 and T47D/182R-2 cell lines. Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. |
| Production Details | T47D/S5 cells grows continuously in presence of 5% fetal calf serum. |
| Research Area | Cancer, Drug Discovery & Development |
| Recommended Growing Conditions | Phenol red free RPMI 1640 + 5% FCS + glutamax + 8µg Insulin/ml |
| Notes |
T47DS5 cells express ER alpha and progesterone receptor. Passage 155 (AL3043, AL3044) |
| Cellosaurus ID | CVCL_1D46 |
References: 8 entries
Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Europe PMC ID: 25885472
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Europe PMC ID: 25706943
Thrane et al. 2014. Oncogene. :. PMID: 25362855.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Europe PMC ID: 25362855
Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Europe PMC ID: 24513268
Add a reference
References: 8 entries
Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Thrane et al. 2014. Oncogene. :. PMID: 25362855.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Add a reference
